Muscular Dystrophy

Muscular dystrophy refers to a range of muscle diseases caused by defects in muscle proteins, leading to death of the muscle cells, with loss of muscle tissue, and weakness. Here are the latest discoveries pertaining to this disease.

September 16, 2020
Review

A Practical Approach to Imaging of the Supplementary Motor Area and Its Subcortical Connections

Current Neurology and Neuroscience Reports
Mar Jiménez de la PeñaManuel Recio Rodríguez
September 18, 2020

Genetic modifiers ameliorate endocytic and neuromuscular defects in a model of spinal muscular atrophy

BMC Biology
Melissa B WalshAnne C Hart
September 16, 2020

Emery-Dreifuss muscular dystrophy as a possible cause of coronary embolism

Cardiology Journal
Atsushi TadaToshihisa Anzai
September 18, 2020
Case Report
Open Access

A team approach in the diagnosis and management of facioscapulohumeral muscular dystrophy: a case report

JSES International
Robert L ParisienXinning Li
September 18, 2020
Case Report
Open Access

An adult nemaline myopathy patient with respiratory and heart failure harboring a novel NEB variant

ENeurologicalSci
Masahiro OharaHiroto Fujigasaki
September 18, 2020

Status Update in the Use of Cell Penetrating Peptides for the Delivery of Macromolecular Therapeutics

Expert Opinion on Biological Therapy
Kaido KurrikoffÜlo Langel
September 15, 2020

Minimal Consequences of CMAH and DBA/2J Background on a FKRP Deficient Model

Journal of Neuromuscular Diseases
Camille VaubourgJessica Bellec
September 17, 2020
Open Access

How the effects of actions become our own

Science Advances
L ZapparoliE Paulesu
September 19, 2020

Effects of endothelin receptor blockade and COX inhibition on intestinal I/R injury in a rat model: Experimental research

International Journal of Surgery
Bercis Imge UcarSezgin Zeren
September 18, 2020

The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement

Multiple Sclerosis : Clinical and Laboratory Research
Lucia MoiolaAgostino Riva
September 18, 2020

Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway

Acta Pharmacologica Sinica
Deng-Qiu XuZhen-Zhou Jiang
September 16, 2020

Effects of Different n6/n3 PUFAs Dietary Ratio on Cardiac Diabetic Neuropathy

Nutrients
Marjan UrlićNatalija Filipović
September 19, 2020
Review

Stem cell therapy for muscular dystrophies

The Journal of Clinical Investigation
Stefano BiressiThomas A Rando
September 15, 2020

Phenotypic Spectrum of Myopathies with Recessive Anoctamin-5 Mutations

Journal of Neuromuscular Diseases
José VázquezEdoardo Malfatti
September 15, 2020
Open Access

Validity of Toluidine Blue test as a diagnostic tool for high risk oral potentially malignant disorders- a multicentre study in Sri Lanka

Journal of Oral Biology and Craniofacial Research
R D JayasingheH K Amarasinghe

Sign up to follow this feed and discover related papers.

Related Feeds

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

© 2020 Meta ULC. All rights reserved
/feed-previews/muscular-dystrophy/fa761a7d-daf6-4117-8a89-e2d1aae1ab5d